About Geranylgeranyl pyrophosphate synthase
Geranylgeranyl pyrophosphate synthase (GGPS1) is a protein
from Homo sapiens identified by UniProt accession
O95749, 300 residues long.
MolForge cross-references it against 0 known binders and
124 disease associations.
Target properties
| Protein name | Geranylgeranyl pyrophosphate synthase |
| UniProt accession | O95749 |
| Gene | GGPS1 |
| Organism | Homo sapiens |
| Length | 300 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (124)
Diseases linked to this target (Open Targets).
- muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome · score 0.68
- multiple sclerosis · score 0.43
- lysosomal storage disease · score 0.43
- Alzheimer disease · score 0.43
- neurodegenerative disease · score 0.43
- Parkinson disease · score 0.43
- Perrault syndrome 1 · score 0.37
- Perrault syndrome 2 · score 0.37
- lean body mass · score 0.26
- body height · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95749-F1 | alphafold | PREDICTED | 94.57 | — |
Amino-acid sequence (300 residues)
MEKTQETVQR ILLEPYKYLL QLPGKQVRTK LSQAFNHWLK VPEDKLQIII EVTEMLHNAS LLIDDIEDNS KLRRGFPVAH SIYGIPSVIN SANYVYFLGL EKVLTLDHPD AVKLFTRQLL ELHQGQGLDI YWRDNYTCPT EEEYKAMVLQ KTGGLFGLAV GLMQLFSDYK EDLKPLLNTL GLFFQIRDDY ANLHSKEYSE NKSFCEDLTE GKFSFPTIHA IWSRPESTQV QNILRQRTEN IDIKKYCVHY LEDVGSFEYT RNTLKELEAK AYKQIDARGG NPELVALVKH LSKMFKEENE
Explore Geranylgeranyl pyrophosphate synthase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets